CL2017000643A1 - Inhibidores de histona desmetilasa - Google Patents

Inhibidores de histona desmetilasa

Info

Publication number
CL2017000643A1
CL2017000643A1 CL2017000643A CL2017000643A CL2017000643A1 CL 2017000643 A1 CL2017000643 A1 CL 2017000643A1 CL 2017000643 A CL2017000643 A CL 2017000643A CL 2017000643 A CL2017000643 A CL 2017000643A CL 2017000643 A1 CL2017000643 A1 CL 2017000643A1
Authority
CL
Chile
Prior art keywords
cancer
compositions
compounds
histone demethylase
useful
Prior art date
Application number
CL2017000643A
Other languages
English (en)
Inventor
Jeffrey Alan Stafford
James Marvin Veal
Young K Chen
Zhe Nie
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of CL2017000643A1 publication Critical patent/CL2017000643A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN EN GENERAL SE RELACIONA CON COMPOSICIONES Y MÉTODOS PARA TRATAR CÁNCER Y ENFERMEDADES NEOPLÁSICAS. SE PROPORCIONAN AQUÍ COMPUESTOS DERIVADOS DE IMIDAZOL-PIRIDINA SUSTITUIDOS Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN DICHOS COMPUESTOS. LOS COMPUESTOS Y COMPOSICIONES OBJETO SON ÚTILES PARA INHIBICIÓN DE ENZIMAS HISTONA DESMETILASA. ADICIONALMENTE, LOS COMPUESTOS Y COMPOSICIONES OBJETO SON ÚTILES PARA EL TRATAMIENTO DE CÁNCER, TAL COMO CÁNCER PANCREÁTICO, CÁNCER DE PRÓSTATA, CÁNCER DE MAMA, CÁNCER DE VEJIGA, CÁNCER DE PULMÓN, CÁNCER GÁSTRICO, LEUCEMIA Y/O MELANOMA Y SIMILARES.</p>
CL2017000643A 2014-09-16 2017-03-16 Inhibidores de histona desmetilasa CL2017000643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051268P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
CL2017000643A1 true CL2017000643A1 (es) 2017-12-01

Family

ID=55533770

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000643A CL2017000643A1 (es) 2014-09-16 2017-03-16 Inhibidores de histona desmetilasa

Country Status (17)

Country Link
US (2) US9676770B2 (es)
EP (1) EP3193881B1 (es)
JP (1) JP6660060B2 (es)
KR (1) KR20170048590A (es)
CN (1) CN107073006A (es)
AU (1) AU2015317904A1 (es)
BR (1) BR112017005128A2 (es)
CA (1) CA2961525A1 (es)
CL (1) CL2017000643A1 (es)
CO (1) CO2017002772A2 (es)
EA (1) EA201790502A1 (es)
EC (1) ECSP17020172A (es)
ES (1) ES2911292T3 (es)
IL (1) IL251103A0 (es)
MX (1) MX2017003464A (es)
SG (1) SG11201702108PA (es)
WO (1) WO2016044342A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
TWI824309B (zh) 2015-11-06 2023-12-01 美商英塞特公司 作為PI3K-γ抑制劑之雜環化合物
US20170190689A1 (en) * 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
JP6970680B2 (ja) * 2016-03-15 2021-11-24 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
MA50398B1 (fr) 2017-10-18 2021-10-29 Incyte Corp Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
SG11202102224UA (en) 2018-09-05 2021-04-29 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
CN111116571B (zh) * 2019-12-27 2022-07-12 吉首大学 含恶唑及三唑双杂环的化合物及其制备与应用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038683A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
DE60133758T2 (de) 2000-10-26 2009-07-02 Amgen Inc., Thousand Oaks Antiphlogistische mittel
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1965782A1 (en) 2005-12-19 2008-09-10 Boehringer Ingelheim International GmbH Use of aminoalcohol derivatives for the treatment of overactive bladder
JP2010540649A (ja) 2007-10-03 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＭＥＴタンパク質の阻害剤
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
CU24077B1 (es) 2009-11-10 2015-03-30 Pfizer DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
ES2834959T3 (es) * 2012-12-06 2021-06-21 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
CA2903081A1 (en) * 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
MX2017003464A (es) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
US9896436B2 (en) * 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors

Also Published As

Publication number Publication date
CO2017002772A2 (es) 2017-06-09
WO2016044342A1 (en) 2016-03-24
EP3193881A1 (en) 2017-07-26
EP3193881A4 (en) 2018-02-21
ECSP17020172A (es) 2017-05-31
JP2017527590A (ja) 2017-09-21
EP3193881B1 (en) 2022-02-09
ES2911292T3 (es) 2022-05-18
JP6660060B2 (ja) 2020-03-04
CA2961525A1 (en) 2016-03-24
KR20170048590A (ko) 2017-05-08
CN107073006A (zh) 2017-08-18
MX2017003464A (es) 2017-07-13
AU2015317904A1 (en) 2017-04-06
EA201790502A1 (ru) 2017-10-31
IL251103A0 (en) 2017-04-30
US20170240529A1 (en) 2017-08-24
BR112017005128A2 (pt) 2018-07-31
US10071984B2 (en) 2018-09-11
US9676770B2 (en) 2017-06-13
US20160108033A1 (en) 2016-04-21
SG11201702108PA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
CL2017000643A1 (es) Inhibidores de histona desmetilasa
CL2016003350A1 (es) Inhibidores de demetilasa-1 especifica de lisina
CO2017002191A2 (es) Inhibidores de desmetilasa-1 específica a lisina
ECSP17006821A (es) Inhibidores de la desmetilasa-1 específica de la lisina
CO2017000359A2 (es) Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa
ECSP15030527A (es) Inhibidores de histona desmetilasa
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
ECSP17006776A (es) Inhibidores de la desmetilasa-1 específica de la lisina
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
ECSP17023551A (es) Inhibidores de histona desmetilasa
ECSP17022542A (es) Inhibidores de la histona desmetilasa